Kidney disease: New technologies translate mechanisms to cure

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2294-2298

  O'Toole, John F ^a   Sedor, John R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; FOCAL GLOMERULOSCLEROSIS; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LEUKOCYTE; MEDICAL RESEARCH; MEMBRANOUS GLOMERULONEPHRITIS; MOLECULAR INTERACTION; PODOCYTE; PRIORITY JOURNAL; REVIEW;

ACUTE KIDNEY INJURY; ANIMALS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PODOCYTES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENAL INSUFFICIENCY, CHRONIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84902180610     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76825     Document Type: Review

References (88)

1. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165- 180.
2. CDC. 2014 National Chronic Kidney Disease Fact Sheet. Atlanta, Georgia, USA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014.
3. Eckardt KU, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;158(9887):158-169.
4. Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013;24(9):1478-1483.
5. Lipkowitz MS, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2012;83(1):114-120.
6. Forsblom C, et al. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2011;22(3):537-544.
7. Rosolowsky ET, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol. 2011;22(3):545-553.
8. Parsa A, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183-2196.
9. Bunn HF. Erythropoietin. Cold Spring Harb Perspect Med. 2013;3(3):a011619.
10. Falk RJ. ASN presidential address 2012: Time to cure kidney disease. J Am Soc Nephrol. 2013;24(7):1040-1043.
11. Atlas of chronic kidney disease and end-stage renal disease in the United States. In: USRDS 2013 Annual Data Report. Bethesda, Maryland, USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
12. Kawabe K, Watanabe TX, Shiono K, Sokabe H. Influence on blood pressure of renal isografts between spontaneously hypertensive and normotensive rats, utilizing the F1 hybrids. Jpn Heart J. 1978;19(6):886-894.
13. Dahl LK, Heine M. Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res. 1975;36(6):692-696.
14. Bianchi G, Fox U, Di Francesco GF, Giovanetti AM, Pagetti D. Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. Clin Sci Mol Med. 1974;47(5):435-448.
15. Dahl LK, Heine M, Thompson K. Genetic influence of the kidneys on blood pressure. Evidence from chronic renal homografts in rats with opposite predispositions to hypertension. Circ Res. 1974;40(4):94-101.
16. Guyton AC. The surprising kidney-fluid mechanism for pressure control - its infinite gain! Hypertension. 1990;16(6):725-730.
17. Crowley SD, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006;103(47):17985-17990.
18. Gonzalez-Villalobos RA, et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest. 2013;123(5):2011-2023.
19. Coffman TM, Crowley SD. Kidney in hypertension: guyton redux. Hypertension. 2008;51(4):811-816.
20. Crowley SD, Coffman TM. The inextricable role of the kidney in hypertension. J Clin Invest. 2014;124(6):2341-2347.
21. Wiig H, et al. Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest. 2013;123(7):2803-2815.
22. Titze J, et al. Spooky sodium balance. Kidney Int. 2014;85(4):759-767.
23. Spencer AG, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6(227):227ra36.
24. Groop PH, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651-1658.
25. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010;53(11):2312-2319.
26. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532-2539.
27. Afkarian M, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-308.
28. Ismail-Beigi F, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-430.
29. Gerstein HC, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-828.
30. Mauer M, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):40-51.
31. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470(7333):204-213.
32. Sandholm N, et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet. 2012;8(9):e1002921.
33. Igo RP, et al. Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study. Am J Nephrol. 2011;33(5):381-389.
34. Pezzolesi MG, et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes mellitus. Diabetes. 2009;58(6):1403-1410.
35. Manolio TA, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747-753.
36. Goldstein DB. The importance of synthetic associations will only be resolved empirically. PLoS Biol. 2011;9(1):e1001008.
37. Lango AH, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature. 2010;467(7317):832-838.
38. Gu Y, et al. Long-term renal changes in the liverspecific glucokinase knockout mouse: implications for renal disease in maturity-onset diabetes of the young 2. Transl Res. 2011;157(3):111-116.
39. Edwards SL, Beesley J, French JD, Dunning AM. Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet. 2013;93(5):779-797.
40. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124(6):2333-2340.
41. Writing Team for the Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159-2167.
42. de Boer IH, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med. 2011;171(5):412-420.
43. Callaway E. Epigenomics starts to make its mark. Nature. 2014;508(7494):22.
44. Murphy TM, Mill J. Epigenetics in health and disease: heralding the EWAS era. Lancet. 2014; pii:S0140-6736 (14) 60269-5.
45. Hopp K, et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest. 2012;122(11):4257-4273.
46. Gallagher AR, Germino GG, Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(2):118-130.
47. Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest. 2014;124(6):2315-2324.
48. Wang X, et al. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats. Kidney Int. 2013;84(5):962-968.
49. Rowe I, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med. 2013;19(4):388-393.
50. Lee S, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22(2):317-326.
51. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest. 2008;118(11):3522-3530.
52. Molitoris BA. Therapeutic translation in acute kidney injury: the epithelial/endothelial axis. J Clin Invest. 2014;124(6):2355-2363.
53. Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest. 2014;124(6):2299-2306.
54. Duffield JS. Macrophages in kidney repair and regeneration. J Am Soc Nephrol. 2011;22(2):199-201.
55. Lichtnekert J, Kawakami T, Parks WC, Duffield JS. Changes in macrophage phenotype as the immune response evolves. Curr Opin Pharmacol. 2013;13(4):555-564.
56. Lebleu VS, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013;19(8):1047-1053.
57. Meyers CM, Briggs JP. Silymarin for diabetic nephropathy: the challenges of botanical product research. Am J Kidney Dis. 2012;60(6):887-889.
58. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013;5(167):167sr1.
59. Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest. 2014;124(6):2325-2332.
60. Beck LH Jr, Salant DJ. Membranous nephropathy: from models to man. J Clin Invest. 2014;124(6):2307-2314.
61. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy [published online ahead of print March 7, 2014]. J Am Soc Nephrol. doi:10.1681/ASN.2013040430.
62. Hastings MC, et al. Biomarkers in IgA nephropathy: relationship to pathogenetic hits. Expert Opin Med Diagn. 2013;7(6):615-627.
63. Wolfe RA, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725-1730.
64. Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9):e1001307.
65. Cravedi P, Heeger PS. Complement as a multifaceted modulator of kidney transplant injury. J Clin Invest. 2014;124(6):2348-2354.
66. Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 2006;20(2):217-226.
67. Hart TC, et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet. 2002;39(12):882-892.
68. Kottgen A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009;41(6):1191-1198.
69. Kottgen A, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010;42(5):376-384.
70. Trudu M, et al. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med. 2013;19(12):1655-1660.
71. Genovese G, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841-845.
72. Tzur S, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128(3):350.
73. Baker P, Broughton Pipkin F. Screening tests for pregnancy-induced hypertension. Prog Obstet Gynaecol. 1993;10(5 pt 1):69-86.
74. Kopp JB, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129-2137.
75. Perez-Morga D, et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science. 2005;309(5733):469-472.
76. Vanhamme L, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 2003;422(6927):83-87.
77. Pays E, Vanhollebeke B, Vanhamme L, Paturiaux-Hanocq F, Nolan DP, Perez-Morga D. The trypanolytic factor of human serum. Nat Rev Microbiol. 2006;4(6):477-486.
78. Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol. 2011;22(11):2119-2128.
79. Reeves-Daniel AM, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011;11(5):1025-1030.
80. Lee BT, et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant. 2012;12(7):1924-1928.
81. Bruggeman LA, et al. Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol. 2013;25(3):634-644.
82. Gebeshuber CA, et al. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med. 2013;19(4):481-487.
83. Reiser J, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113(10):1390-1397.
84. Yu CC, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369(25):2416-2423.
85. Fiorina P, et al. Role of podocyte B7-1 in diabetic nephropathy [published online ahead of print March 27, 2014]. J Am Soc Nephrol. doi:10.1681/ASN.2013050518.
86. Genovese MC, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005;353(11):1114-1123.
87. Gadegbeku CA, et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013;83(4):749-756.
88. Barisoni L, et al. Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE). Clin J Am Soc Nephrol. 2013;8(8):1449-1459.